Sarepta, SRPT and ptc therapeutics
BofA lowered the firm’s price target on Sarepta (SRPT) to $210 from $217 and keeps a Buy rating on the shares. Management is confident in FY25 ...
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, today’s program is being recorded. At this time, I’d like to turn the call ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Amedisys ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results